CASE REPORT article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1610710
This article is part of the Research TopicOvercoming Resistance to Immune Checkpoint Inhibitors: Mechanisms and Strategies in Cancer TherapyView all 3 articles
Cadonilimab plus anlotinib with radiotherapy for lung adenocarcinoma with pancreatic metastasis in posterior line therapy: A case report
Provisionally accepted
- North Sichuan Medical College, Nanchong, Sichuan Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Advanced lung adenocarcinoma with driver gene-negative patients faces the clinical dilemma of lack of options and poor prognosis in posterior line therapy.Although immune checkpoint inhibitors (ICIs) combined with anti-angiogenic offer new way for these patients, the treatment strategy still needs to be further explored. A special case was reported in this study, the advanced lung adenocarcinoma with pancreatic metastases patient received cadonilimab plus anlotinib with radiotherapy for pancreatic metastases got 11 months of progress free survival (PFS) with minor side effects. The results confirm the value of cadonilimab and anlotinib in posterior line therapy of advanced lung adenocarcinoma, providing a new treatment strategy for patients.
Keywords: Cadonilimab, Anlotinib, Lung Adenocarcinoma, Pancreatic metastasis, Radiotherapy
Received: 12 Apr 2025; Accepted: 23 Jun 2025.
Copyright: © 2025 Yang, Li, Pang, Zhang, Zeng, Gui and ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: daiyuan ma, North Sichuan Medical College, Nanchong, Sichuan Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.